By Abigail Townsend
Date: Wednesday 20 Oct 2021
(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.
| Currency | US Dollars |
| Share Price | $ 169.31 |
| Closing Price Change | $ -8.99 |
| % Change | 0.00 % |
| 52 Week High | $0.00 |
| 52 Week Low | $0.00 |
| Volume | 0 |
| Shares Issued | 145.80m |
| RiskGrade | 259 |
| Time | Volume / Share Price |
| 14:57 | 100 @ $168.80 |
| 14:57 | 100 @ $168.79 |
| 14:57 | 100 @ $168.80 |
| 14:57 | 100 @ $168.80 |
| 14:57 | 400 @ $168.90 |
You are here: research